PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 187 filers reported holding PDL BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is 2.92 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $53,000 | +8.2% | 16,713 | +0.0% | 0.00% | – |
Q2 2020 | $49,000 | -71.5% | 16,709 | -72.6% | 0.00% | – |
Q1 2020 | $172,000 | -25.2% | 60,923 | -14.1% | 0.00% | – |
Q4 2019 | $230,000 | -95.8% | 70,926 | -97.2% | 0.00% | -100.0% |
Q3 2019 | $5,462,000 | -45.0% | 2,528,693 | -20.1% | 0.00% | -50.0% |
Q2 2019 | $9,935,000 | -13.7% | 3,164,073 | +2.2% | 0.00% | -20.0% |
Q1 2019 | $11,514,000 | +36.2% | 3,095,142 | +6.2% | 0.01% | +25.0% |
Q4 2018 | $8,454,000 | +10.2% | 2,915,660 | -0.1% | 0.00% | +33.3% |
Q3 2018 | $7,672,000 | +12.5% | 2,917,493 | +0.1% | 0.00% | 0.0% |
Q2 2018 | $6,819,000 | -16.2% | 2,914,186 | +5.3% | 0.00% | -25.0% |
Q1 2018 | $8,135,000 | +5.6% | 2,767,162 | -1.6% | 0.00% | +33.3% |
Q4 2017 | $7,706,000 | -30.3% | 2,811,842 | -13.8% | 0.00% | -40.0% |
Q3 2017 | $11,063,000 | +31.4% | 3,263,385 | -4.3% | 0.01% | +25.0% |
Q2 2017 | $8,421,000 | +6.8% | 3,409,353 | -1.9% | 0.00% | 0.0% |
Q1 2017 | $7,886,000 | +1964.4% | 3,473,956 | +1823.9% | 0.00% | – |
Q4 2016 | $382,000 | -58.7% | 180,570 | -34.5% | 0.00% | -100.0% |
Q3 2016 | $925,000 | +1.6% | 275,882 | -4.7% | 0.00% | 0.0% |
Q2 2016 | $910,000 | +0.8% | 289,354 | +6.7% | 0.00% | 0.0% |
Q1 2016 | $903,000 | -14.2% | 271,301 | -8.7% | 0.00% | 0.0% |
Q4 2015 | $1,052,000 | -73.2% | 297,173 | -61.9% | 0.00% | -66.7% |
Q3 2015 | $3,919,000 | -26.3% | 779,125 | -5.8% | 0.00% | -25.0% |
Q2 2015 | $5,316,000 | -18.3% | 826,711 | -10.6% | 0.00% | -20.0% |
Q1 2015 | $6,507,000 | -63.1% | 924,805 | -59.5% | 0.01% | -54.5% |
Q4 2014 | $17,617,000 | +26.5% | 2,284,894 | +22.6% | 0.01% | +10.0% |
Q3 2014 | $13,927,000 | -37.0% | 1,864,394 | -18.4% | 0.01% | -33.3% |
Q2 2014 | $22,114,000 | +111.7% | 2,284,485 | +81.7% | 0.02% | +87.5% |
Q1 2014 | $10,448,000 | +28.0% | 1,257,272 | +30.0% | 0.01% | +33.3% |
Q4 2013 | $8,162,000 | +23.9% | 967,016 | +17.0% | 0.01% | +20.0% |
Q3 2013 | $6,585,000 | +4.3% | 826,221 | +1.0% | 0.01% | 0.0% |
Q2 2013 | $6,316,000 | – | 818,075 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |